Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring: A nationwide cohort study

S Friedman; M D Larsen; B Magnussen; L R Jølving; P de Silva; B M Nørgård

doi:10.1016/j.reprotox.2017.08.013

Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring: A nationwide cohort study

S Friedman, M D Larsen, B Magnussen, L R Jølving, P de Silva, B M Nørgård

KI, Klinisk Epidemiologi

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

277 Downloads (Pure)

Abstrakt

PURPOSE: We examined the effect of preconception paternal use of azathioprine (AZA)/6-mercaptopurine (6-MP) or methotrexate (MTX) and the risk of adverse long-term outcomes in the offspring.

METHODS: This study included all children born in Denmark from 1 January 1997 through 2013. Exposed cohort: children fathered by men who used AZA/6-MP (N=735) or MTX (N=209) within three months before conception; unexposed cohort: children fathered by men who did not use AZA/6-MP/MTX (N=1,056,524).

OUTCOMES: malignancies, autism spectrum disorders (ASD)/schizophrenia/psychosis, and attention deficit hyperactivity disorder (ADHD).

RESULTS: Outcomes: of children: AZA/6-MP exposure: one with leukemia (0.14%), one with ASD/schizophrenia (0.14%) and three with ADHD (0.41%); MTX exposure: three with ADHD (1.4%). Unexposed: 1710 with malignancies (0.16%), 2107 with ASD/schizophrenia (0.20%), 2799 with ADHD (0.26%). Median follow up times were 6.7 [IQR:3.6-11.3] and 9.9 [IQR:5.7-14.3] years respectively.

CONCLUSIONS: There was no negative impact of paternal preconception use of AZA/6-MP/MTX on selected childhood health outcomes.

Originalsprog	Engelsk
Tidsskrift	Reproductive toxicology (Elmsford, N.Y.)
Vol/bind	73
Sider (fra-til)	196-200
ISSN	0890-6238
DOI	https://doi.org/10.1016/j.reprotox.2017.08.013
Status	Udgivet - 2017

Dokumenter og links

10.1016/j.reprotox.2017.08.013

Paternal use of azathioprine_6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring_A nationwide coAccepteret manuskript, 407 KBLicens: CC BY-NC-ND

Fingeraftryk Dyk ned i forskningsemnerne om 'Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring: A nationwide cohort study'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Friedman, S., Larsen, M. D., Magnussen, B., Jølving, L. R., de Silva, P., & Nørgård, B. M. (2017). Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring: A nationwide cohort study. Reproductive toxicology (Elmsford, N.Y.), 73, 196-200. https://doi.org/10.1016/j.reprotox.2017.08.013

@article{90194ccc68804696949c9b0f191bf78f,

title = "Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring: A nationwide cohort study",

abstract = "PURPOSE: We examined the effect of preconception paternal use of azathioprine (AZA)/6-mercaptopurine (6-MP) or methotrexate (MTX) and the risk of adverse long-term outcomes in the offspring.METHODS: This study included all children born in Denmark from 1 January 1997 through 2013. Exposed cohort: children fathered by men who used AZA/6-MP (N=735) or MTX (N=209) within three months before conception; unexposed cohort: children fathered by men who did not use AZA/6-MP/MTX (N=1,056,524).OUTCOMES: malignancies, autism spectrum disorders (ASD)/schizophrenia/psychosis, and attention deficit hyperactivity disorder (ADHD).RESULTS: Outcomes: of children: AZA/6-MP exposure: one with leukemia (0.14%), one with ASD/schizophrenia (0.14%) and three with ADHD (0.41%); MTX exposure: three with ADHD (1.4%). Unexposed: 1710 with malignancies (0.16%), 2107 with ASD/schizophrenia (0.20%), 2799 with ADHD (0.26%). Median follow up times were 6.7 [IQR:3.6-11.3] and 9.9 [IQR:5.7-14.3] years respectively.CONCLUSIONS: There was no negative impact of paternal preconception use of AZA/6-MP/MTX on selected childhood health outcomes.",

keywords = "Journal Article",

author = "S Friedman and Larsen, {M D} and B Magnussen and J{\o}lving, {L R} and {de Silva}, P and N{\o}rg{\aa}rd, {B M}",

year = "2017",

doi = "10.1016/j.reprotox.2017.08.013",

language = "English",

volume = "73",

pages = "196--200",

journal = "Reproductive Toxicology",

issn = "0890-6238",

publisher = "Elsevier",

}

Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring : A nationwide cohort study. / Friedman, S; Larsen, M D; Magnussen, B; Jølving, L R; de Silva, P; Nørgård, B M.

I: Reproductive toxicology (Elmsford, N.Y.), Bind 73, 2017, s. 196-200.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring

T2 - A nationwide cohort study

AU - Friedman, S

AU - Larsen, M D

AU - Magnussen, B

AU - Jølving, L R

AU - de Silva, P

AU - Nørgård, B M

PY - 2017

Y1 - 2017

N2 - PURPOSE: We examined the effect of preconception paternal use of azathioprine (AZA)/6-mercaptopurine (6-MP) or methotrexate (MTX) and the risk of adverse long-term outcomes in the offspring.METHODS: This study included all children born in Denmark from 1 January 1997 through 2013. Exposed cohort: children fathered by men who used AZA/6-MP (N=735) or MTX (N=209) within three months before conception; unexposed cohort: children fathered by men who did not use AZA/6-MP/MTX (N=1,056,524).OUTCOMES: malignancies, autism spectrum disorders (ASD)/schizophrenia/psychosis, and attention deficit hyperactivity disorder (ADHD).RESULTS: Outcomes: of children: AZA/6-MP exposure: one with leukemia (0.14%), one with ASD/schizophrenia (0.14%) and three with ADHD (0.41%); MTX exposure: three with ADHD (1.4%). Unexposed: 1710 with malignancies (0.16%), 2107 with ASD/schizophrenia (0.20%), 2799 with ADHD (0.26%). Median follow up times were 6.7 [IQR:3.6-11.3] and 9.9 [IQR:5.7-14.3] years respectively.CONCLUSIONS: There was no negative impact of paternal preconception use of AZA/6-MP/MTX on selected childhood health outcomes.

AB - PURPOSE: We examined the effect of preconception paternal use of azathioprine (AZA)/6-mercaptopurine (6-MP) or methotrexate (MTX) and the risk of adverse long-term outcomes in the offspring.METHODS: This study included all children born in Denmark from 1 January 1997 through 2013. Exposed cohort: children fathered by men who used AZA/6-MP (N=735) or MTX (N=209) within three months before conception; unexposed cohort: children fathered by men who did not use AZA/6-MP/MTX (N=1,056,524).OUTCOMES: malignancies, autism spectrum disorders (ASD)/schizophrenia/psychosis, and attention deficit hyperactivity disorder (ADHD).RESULTS: Outcomes: of children: AZA/6-MP exposure: one with leukemia (0.14%), one with ASD/schizophrenia (0.14%) and three with ADHD (0.41%); MTX exposure: three with ADHD (1.4%). Unexposed: 1710 with malignancies (0.16%), 2107 with ASD/schizophrenia (0.20%), 2799 with ADHD (0.26%). Median follow up times were 6.7 [IQR:3.6-11.3] and 9.9 [IQR:5.7-14.3] years respectively.CONCLUSIONS: There was no negative impact of paternal preconception use of AZA/6-MP/MTX on selected childhood health outcomes.

KW - Journal Article

U2 - 10.1016/j.reprotox.2017.08.013

DO - 10.1016/j.reprotox.2017.08.013

M3 - Journal article

C2 - 28844800

VL - 73

SP - 196

EP - 200

JO - Reproductive Toxicology

JF - Reproductive Toxicology

SN - 0890-6238

ER -